Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online May 22, 2007
Diabetes Care 30:1968-1971, 2007
DOI: 10.2337/dc07-0157
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-0157v1
30/8/1968    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nilsson, C.
Right arrow Articles by Landin-Olsson, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nilsson, C.
Right arrow Articles by Landin-Olsson, M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition/Psychosocial Research
Original Article

Presence of GAD Antibodies During Gestational Diabetes Mellitus Predicts Type 1 Diabetes

Charlotta Nilsson, MD1, Dag Ursing, MD1, Carina Törn, BSC, PHD2, Anders Åberg, MD, PHD3 and Mona Landin-Olsson, MD, PHD1

1 Department of Endocrinology and Diabetology, Lund University Hospital, Lund, Sweden
2 Department of Clinical Science, Lund University Hospital, Lund, Sweden
3 Department of Obstetrics and Gynaecology, Lund University Hospital, Lund, Sweden

Address correspondence and reprint requests to Mona Landin-Olsson, Department of Endocrinology and Diabetology, Lund University Hospital, S- 221 85 Lund, Sweden. E-mail: mona.landin-olsson{at}med.lu.se

OBJECTIVE—We sought to study the frequency of ß-cell–specific autoantibody markers in women with gestational diabetes mellitus (GDM) and to follow these women to estimate the risk of later development of type 1 diabetes.

RESEARCH DESIGN AND METHODS—Of 385 pregnant women with GDM during 1995–2005 in the district of Lund, 24 (6%) women were found positive for at least one of the following: islet cell antibody (ICA), GAD antibody (GADA), or tyrosine phosphatase antibody (IA-2A). The women were followed and autoantibodies reanalyzed. Those who had not developed diabetes did an oral glucose tolerance test. The frequencies of known risk factors for GDM were compared in women with GDM with and without pancreatic autoantibodies.

RESULTS—Among the autoantibody-positive women, 50% had developed type 1 diabetes compared with none among the GDM control subjects (P = 0.001), 21% had impaired fasting glucose or impaired glucose tolerance compared with 12.5% among control subjects (P = 0.3), and none had developed type 2 diabetes compared with 12.5% among control subjects (P = 0.1).

CONCLUSIONS—Autoantibody screening in pregnant women with GDM and follow-up after delivery should be considered for early recognition of type 1 diabetes.

Abbreviations: GADA, GAD antibody • GDM, gestational diabetes mellitus • IA-2A, tyrosine phosphatase antibody • ICA, islet cell antibody • IFG, impaired fasting glucose • IGT, impaired glucose tolerance • OGTT, oral glucose tolerance test


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.